HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Raises Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has maintained a Neutral rating on Co-Diagnostics (NASDAQ:CODX) but increased the price target from $2 to $3.

November 13, 2023 | 3:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Co-Diagnostics' Neutral rating is maintained by HC Wainwright & Co., but the price target is raised from $2 to $3, indicating a potential upside.
The increase in price target from $2 to $3 by a reputable analyst firm suggests a positive outlook on the stock's value, which could lead to short-term price appreciation. However, the Neutral rating indicates that the firm does not see significant momentum or changes in fundamentals that would justify a more bullish stance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100